flucytosine has been researched along with Candidiasis, Genital in 21 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with Candida glabrata vaginitis." | 7.72 | Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. ( Chaim, W; Leaman, D; Nagappan, V; Sobel, JD, 2003) |
| "The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with Candida glabrata vaginitis." | 3.72 | Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. ( Chaim, W; Leaman, D; Nagappan, V; Sobel, JD, 2003) |
| "Vulvovaginal candidiasis is a global issue of concern due to its association with economic costs, sexually transmitted infections, and ascending genital tract infection." | 1.48 | Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( Abebaw, Y; Bitew, A, 2018) |
| "Computed tomography revealed hydrocephalus and signs of increased cerebrospinal fluid (CSF) pressure." | 1.29 | [Unusual course of candidiasis of the central nervous system]. ( Lisch, S; Steudel, WI, 1994) |
| "Congenital candida infection is a rare disease, although the incidence of candida vaginitis during pregnancy is high." | 1.29 | [Congenital candida infections]. ( Bollinger, M; Kühnert, M; Loewenich, V; Schlösser, RL; Zubcov, A, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (38.10) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitew, A | 1 |
| Abebaw, Y | 1 |
| Hettiarachchi, N | 1 |
| Hetticarachchi, N | 1 |
| Ashbee, HR | 1 |
| Wilson, JD | 1 |
| Iavazzo, C | 1 |
| Gkegkes, ID | 1 |
| Zarkada, IM | 1 |
| Falagas, ME | 1 |
| Challenor, R | 1 |
| Pinsent, S | 1 |
| Ekanayaka, R | 1 |
| Shann, S | 1 |
| Wilson, J | 1 |
| Sobel, JD | 2 |
| Chaim, W | 1 |
| Nagappan, V | 1 |
| Leaman, D | 1 |
| Jiang, XX | 1 |
| Lu, SM | 1 |
| Lynch, ME | 1 |
| Lisch, S | 1 |
| Steudel, WI | 1 |
| Schlösser, RL | 1 |
| Zubcov, A | 1 |
| Bollinger, M | 1 |
| Kühnert, M | 1 |
| Loewenich, V | 1 |
| Sood, G | 1 |
| Nyirjesy, P | 1 |
| Weitz, MV | 1 |
| Chatwani, A | 1 |
| White, DJ | 1 |
| Habib, AR | 1 |
| Vanthuyne, A | 1 |
| Langford, S | 1 |
| Symonds, M | 1 |
| Odds, FC | 1 |
| Kivinen, S | 1 |
| Tarkkila, T | 1 |
| Laakso, L | 1 |
| Laakso, K | 1 |
| Argemi, J | 1 |
| Valls, A | 1 |
| Casanova-Bellido, M | 1 |
| Lechuga, JL | 1 |
| Botet, F | 1 |
| Rubio-Lotvin, B | 1 |
| González Ansorena, R | 1 |
| Bolio Arista, R | 1 |
| Ruiz Moreno, JA | 1 |
| Speller, DC | 1 |
| Warnock, DW | 1 |
| Weber, S | 1 |
| Polak-Wyss, A | 1 |
| Grob, PJ | 1 |
| Wüthrich, B | 1 |
| Holt, RJ | 1 |
| Seligman, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Comparison of Boric Acid Versus Terconazole in Treatment of Recurrent Vulvovaginal Candidiasis[NCT04208555] | 76 participants (Anticipated) | Interventional | 2020-01-15 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flucytosine and Candidiasis, Genital
| Article | Year |
|---|---|
Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Antifungal Agents; Azoles; Biological Av | 2011 |
1 trial available for flucytosine and Candidiasis, Genital
| Article | Year |
|---|---|
Short-term topical treatment of vulvovaginal candidiasis with the combination of 5-fluorocytosine and candicidin.
Topics: Administration, Topical; Adult; Antifungal Agents; Candicidin; Candidiasis, Vulvovaginal; Cytosine; | 1979 |
19 other studies available for flucytosine and Candidiasis, Genital
| Article | Year |
|---|---|
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Caspofungin; Cros | 2018 |
Prevalence and management of non-albicans vaginal candidiasis.
Topics: Administration, Intravaginal; Amphotericin B; Antifungal Agents; Candidiasis, Vulvovaginal; Drug The | 2010 |
A case series of the management of symptomatic azole-resistant candida.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Azoles; Candida albicans; Candidiasis, V | 2012 |
Treatment of Candida glabrata using topical amphotericin B and flucytosine.
Topics: Administration, Intravaginal; Adult; Amphotericin B; Antifungal Agents; Candidiasis, Vulvovaginal; D | 2003 |
Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Boric Acids; Candida glabrata; | 2003 |
[DNA and RNA random amplification polymorphism in 5-flurocytosine-resistant strains of Candida albicans from revul-vaginal candidasis].
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; DNA, Fungal; Drug | 2005 |
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Fem | 1994 |
[Unusual course of candidiasis of the central nervous system].
Topics: Adolescent; Amphotericin B; Antitubercular Agents; Brain Diseases; Candida albicans; Candidiasis; Ca | 1994 |
[Congenital candida infections].
Topics: Adult; Amniocentesis; Amphotericin B; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candid | 1993 |
Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.
Topics: Antifungal Agents; Boric Acids; Candidiasis, Vulvovaginal; Female; Flucytosine; Humans; Middle Aged; | 2000 |
Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
Topics: Adult; Amphotericin B; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Combinations; Female; Fluc | 2001 |
Problems in the laboratory assessment of antifungal activity.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Evaluation, Pre | 1979 |
Candida infections.
Topics: Amphotericin B; Candidiasis; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; C | 1979 |
[Treatment of vaginal candidiasis with 5-fluorocytosine].
Topics: Administration, Topical; Adult; Candidiasis, Vulvovaginal; Cytosine; Drug Evaluation; Female; Flucyt | 1975 |
Letter: Vaginal candidosis.
Topics: Amphotericin B; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Female; Flucytosine; Humans | 1976 |
[The resistance behavior of yeast isolates from defined patient groups to 5-fluorocytosine].
Topics: Candida; Candidiasis; Candidiasis, Oral; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Fema | 1991 |
Transfer factor therapy in a patient with chronic vaginal candidiasis.
Topics: Adult; Antibodies, Fungal; Antigens, Fungal; Candida albicans; Candidiasis, Vulvovaginal; Chronic Di | 1974 |
Letter: Treatment of vulval candidiasis with 5-fluorocytosine.
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Cytosine; Drug Resistance, Microbial; Feces; | 1974 |
Letter: Treatment of vulval candidiasis with 5-fluorocytosine.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Cytosine; Diarrhea; Female; F | 1974 |